The missing link: an antenna-centric adoption scenario for broadband from space
New space companies are planning to launch LEO satellites to provide broadband internet everywhere on earth. But with antennas for satellite receivers at consumer price points still out of reach, how will users be connected?
Design for adherence: a model for predicting and improving medication adherence
Medication adherence is often studied after a drug or delivery device has been developed, but what if we were able to predict levels of adherence for a particular drug delivery device during development?
AI: Fashion or Future?
Artificial Intelligence could be the solution to all our woes or the most over-hyped technology of our age. Even defining AI is problematical, given that we have trouble defining what regular intelligence is. But what are the true capabilities of AI?
IoT Connectivity – Where’s the Value?
How can connectivity service suppliers generate revenues that are sustainable and scalable from the IoT? Value-based approaches are needed to meet the interests of all participants over the longer term.
Beyond pixel number: Where next for endoscopic imaging capabilities?
Relentless progress in imaging sensors driven by the smart phone camera revolution is beginning to transform the optical capabilities of endoscopes. Beyond pixel number, this also raises the prospect of challenger business models that offer altogether new imaging capabilities, or disposable endoscopes.
Can we imagine a future of personalised medicine based on the analysis of lipids and carbohydrates?
DNA to RNA to protein – from this simple but powerful concept was born first biotechnology and then personalised medicine. But are we missing something? Can we imagine a future of personalised medicine based on the analysis of lipids and carbohydrates?
Driving Cell Therapy Innovation: Applying Key Lessons from the Evolution and Commercialization of Protein-Based Therapies
Bioprocess International Conference in Boston panel.
New dimensions in 3D bioprinting
Late stage failures in drug development are extremely costly for pharmaceutical companies and stifle innovation. Now non-traditional methods such as 3D bioprinting are being brought to bear on this challenge.
Navigating the market for “PoC” diagnostic systems
Several companies have developed, or are currently developing, products for the “point-of-care” molecular diagnostics market. In reality, the molecular diagnostics market is heterogeneous, and few applications are likely to arise truly at the point of care—indeed “point-of-clinic” would be a better description for this market.
Predicting failure rates in cell therapy manufacturing: is one in a million good enough?
Autologous cell therapy has had some remarkable clinical success, but to get to where it is today, industry has relied heavily on repurposed R&D equipment to manufacture individual batches of cell therapy.